Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SIM0278 in Healthy Chinese Subjects
NCT06022354Phase 1Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Aug 2023
- Primary completion
- Mar 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SIM0278 in atopic dermatitis (AD) (11 cohorts), sponsored by Simcere Pharmaceutical Group. Primary endpoint: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events. Started Aug 2023; status: completed.
02
Drugs
SIM0278
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06022354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022354.